European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

EUROpean consortium on NEUTralising antibodies using gp41

Cel

There is now an increasingly solid body of scientific evidence which demonstrates that the binding of small molecular weight compounds, peptides and antibodies (Abs) to fusion-intermediate conformations of gp41 leads to an inhibition of HIV cell entry. The principal aim of this project is to exploit this information by establishing a platform where gp41-derived vaccine candidates will be designed to elicit neutralising Abs. Several families of immunogens which mimic gp41 in its fusion intermediate conformations are already available and others will be designed using modelisation approaches. Candidates will be submitted to a thorough biophysical characterisation followed by a preclinical development in order to identify the most promising for clinical evaluation. A crucial selection parameter is the capacity of antigens to elicit neutralising Abs using internationally standardized assays. Since sexual transmission accounts for more than 90% of HIV infection, the capacity of Abs to inhibit infection at the mucosal level will also be determined. This cross-disciplinary project gathers top European scientists with expertise in protein engineering and characterisation, adjuvantation, formulation for systemic and mucosal delivery, evaluation of functional antibody response, efficacy testing in animal models, medium to large scale vaccine production as well as conduct of clinical trials in both developed and third-world countries. In contrast to previous more empirical attempts, this project is based on the rational exploitation of the knowledge on the mechanism of HIV entry and is thus a promising approach to generate a protective vaccine. It will be the first European project targeting intermediate conformations of gp41 and it could complement/synergize other international strategies focusing on the membrane proximal region of gp41 or gp140 trimer to induce neutralising Abs or aiming at reducing the viral load by eliciting a cellular immunity against HIV.

Dziedzina nauki

Słowa kluczowe

Program(-y)

Temat(-y)

Zaproszenie do składania wniosków

FP7-HEALTH-2007-A
Zobacz inne projekty w ramach tego zaproszenia

System finansowania

CP-IP - Large-scale integrating project

Koordynator

SANOFI PASTEUR SA
Wkład UE
€ 1 067 425,58
Adres
14 ESPACE HENRY VALLEE
69007 Lyon
Francja

Zobacz na mapie
Region
Auvergne-Rhône-Alpes Rhône-Alpes Rhône
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt administracyjny
Delphine Jullien
Linki
Koszt całkowity
Brak danych

Uczestnicy (18)

Udostępnij tę stronę

Pobierz

Ostatnia aktualizacja: 29 Maja 2017

Moja broszura

Permalink: https://cordis.europa.eu/project/id/201038/pl

European Union, 2024